Journal of Drugs in Dermatology最新文献

{"title":"Clinical Utility of TRPV1 Modulation for Skincare Sensitivity.","authors":"Rohan Shah, Nalini Kaul, Isabella Tan, Anthony Rossi","doi":"10.36849/JDD.8680","DOIUrl":"10.36849/JDD.8680","url":null,"abstract":"<p><p>The Transient Receptor Potential Vanilloid 1 (TRPV1) protein, originally recognized for its role in modulating peripheral sensory neurons and transmitting pain and itch signals, has been increasingly implicated in various dermatological processes. TRPV1 is widely expressed in skin cells, including keratinocytes, fibroblasts, and mast cells, making it a promising target for treating inflammatory skin diseases, skin sensitivity, wound healing, and aging. Activation of TRPV1 by environmental stressors, such as heat and ultraviolet (UV) exposure, induces pro-inflammatory responses and contributes to the degradation of collagen, exacerbating conditions like chronic itch, atopic dermatitis, and dermatoheliosis. This study evaluates the effectiveness of topical formulations containing a sea anemone biomimetic peptide (SABMP), a TRPV1 antagonist, in improving skin texture, elasticity, hydration, and rejuvenation. Clinical trials involved participants with self-perceived sensitive skin, who applied the test formulations for 4 weeks. Results demonstrated significant improvements in skin texture, elasticity, and reductions in erythema and fine lines, highlighting the potential of TRPV1-targeting peptides as an alternative to conventional treatments like retinoids and Vitamin C, particularly for individuals with sensitive skin. The study underscores the clinical utility of TRPV1 antagonism in skin care, offering a novel approach to managing skin sensitivity and aging. These findings suggest that TRPV1-targeting peptides can provide a safe and effective treatment modality for enhancing skin quality and addressing conditions such as atopic dermatitis, rosacea, and acne. J Drugs Dermatol. 2025;24(4):366-371. doi:10.36849/JDD.8680.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"366-370"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The State of the Clinical Management Union: A Cross-Sectional Survey of Persons With Hidradenitis Suppurativa.","authors":"Andeulazia Murdock, Cleo Whiting, Sara Abdel Azim, Savanna I Vidal, Nikita Menta, Brindley Brooks, Adam Friedman","doi":"10.36849/JDD.8867","DOIUrl":"10.36849/JDD.8867","url":null,"abstract":"<p><strong>Background: </strong>Hidradenitis suppurativa (HS) is a chronic autoinflammatory condition notable for a high psychosocial burden on patients. This burden is theorized to be linked to patient dissatisfaction due to the paucity of treatment options.</p><p><strong>Objectives: </strong>This study assessed respondent perceptions of current and emerging HS treatments and their impact on quality of life.</p><p><strong>Methods: </strong>An IRB-exempt (IRB#: NCR235179) survey was distributed via the HSconnect.org listserv for respondents &ge;18 years old. Of 501 responses, 423 (84.4%) completed the entire survey.</p><p><strong>Results: </strong>Less than 20% of respondents were satisfied or very satisfied with current treatment options (76/423). Of respondents with self-reported disease severity of Hurley stage II or III (51%, 244/483), only 39% were being treated with biologics and/or 26% hormone therapy, indicating undertreatment per current HS guidelines. Most respondents (74%) were unaware of Federal Drug Administration (FDA)-approved treatments and 56% reported that their dermatologist or healthcare provider had not discussed these options with them. More than half of respondents (60%, 254/423) felt it was important to have FDA-approved therapies, believing it would lead to improved physical health (86%), mental health (78%), and/or personal relationships (60%).</p><p><strong>Conclusions: </strong>In a large cross-sectional survey of patients with HS, dissatisfaction with current treatment options was expressed by a minority of respondents and likely results from both undertreatment and gaps in knowledge of current FDA-approved therapies. Enhancing patient-provider education about off-label and FDA-approved therapies, including established and emerging treatment options, guidelines for use, and their adverse effects, can dramatically improve the quality of life for persons living with HS. &nbsp; J Drugs Dermatol. 2025;24(4):381-385. doi:10.36849/JDD.8867.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"381-385"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Top Chief Complaints and Diagnoses for Outpatient Dermatology Patients of Color.","authors":"Arielle Carolina Mora Hurtado, Sarah Gonzalez, Nicole C Syder, Melissa Gonzalez, Sanmeet Atwal, Kayla Blair, Ivan Rodriguez, Audrey Hao, Autumn L Saizan, Simone N Montgomery, Jack Rodman, Nada Elbuluk","doi":"10.36849/JDD.8532","DOIUrl":"10.36849/JDD.8532","url":null,"abstract":"<p><strong>Background: </strong>By 2044, people with skin of color (SOC) in the United States are projected to become the majority of the population, yet research and practice gaps remain regarding the dermatologic conditions most common and concerning to populations with SOC.1,2 Objective: To investigate the most common outpatient dermatologic chief complaints and diagnoses in patients with SOC.</p><p><strong>Methods: </strong>A retrospective chart review was conducted investigating the top chief complaints and diagnoses in children and adult patients with SOC seen at the University of Southern California outpatient dermatology clinics over 10 years, from 2009 to 2019.</p><p><strong>Results: </strong>A total of 4572 individuals were identified (2326 [58.9%] female; mean age [SD]: 46.0 [19.9] years). The 5 most common skin concerns were skin examination (21.5%), bumps/growths (20.8%), rash (19.8%), acne (10.0%), and skin discoloration (8.5%). The 5 most common diagnoses were benign nevi/neoplasm (38.8%), followed by dermatitis (20.8%), acne (13.3%), eczema and/or xerosis (9.0%), and dyspigmentation (7.7%). Differences were observed across racial/ethnic, age, and gender groups.</p><p><strong>Conclusion: </strong>Findings from this study contribute valuable insights regarding the potential motivations for seeking dermatologic care across various demographical groups, underscoring the importance of patient-centered, evidence-based, and culturally competent care in the diagnosis and treatment of dermatological disease across diverse populations. J Drugs Dermatol. 2025;24(4):403-409. doi:10.36849/JDD.8532R1.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"403-409"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-Generated Educational Curriculum on Facial Neurotoxin Injections: Assessment of Educational Content, Curriculum Structure, and Course Logistics.","authors":"Jad Abi-Rafeh, Leila Cattelan, Brian Bassiri-Tehrani, Jacob Marks, Roy Kazan, Sachin Shridharani, Mark Albert, Andreas Nikolis, Mirko S Gilardino, Foad Nahai","doi":"10.36849/JDD.8331","DOIUrl":"10.36849/JDD.8331","url":null,"abstract":"<p><strong>Background: </strong>Large language models (LLMs) have revolutionized the way physicians access and leverage artificial intelligence (AI). The potential role of AI in facilitating aesthetic medical education remains to be established.</p><p><strong>Objectives: </strong>The present study aims to assess AI&rsquo;s ability in developing an educational curriculum for the purpose of training physician and nurse injectors in facial botulinum toxin injections.</p><p><strong>Methods: </strong>An AI model was leveraged in line with the study's objectives; five expert injectors and educators validated its performance.</p><p><strong>Results: </strong>Ten suggested steps for curriculum design and implementation were proposed by AI. A list of 12-course learning objectives and a suggested curriculum overview were provided. A 2-day schedule with appropriate session allocations was created, along with a 49-paged curriculum compendium generated entirely by AI. A 9-step approach towards implementation of hands-on practice sessions was provided, complete with quantities of equipment needed. Rubrics evaluating trainees&rsquo; practical performance, and a form soliciting feedback were created. Budget estimates for anticipated costs and finances were also provided, along with 12 target cities with potential dates and venues, 12 suggested instructors, guidelines for obtaining sponsorships, draft sponsorship packages, and a list of potential sponsors.</p><p><strong>Conclusion: </strong>Validation of AI performance in the development of an educational course for facial toxin injections demonstrated promising utility for course design and implementation logistics. While AI performance remains imperfect and can never replace human educators, AI can provide a practical framework for physicians in the development and implementation of large-scale educational endeavors in aesthetic medicine and beyond. J Drugs Dermatol. 2025;24(4):e19-e29. doi:10.36849/JDD.e8331.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"e19-e29"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"INDIVIDUAL ARTICLE: Breaking Barriers: Advancing Cosmeceuticals and Integrated Skincare for Skin of Color.","authors":"Jared Jagdeo","doi":"10.36849/JDD.41491","DOIUrl":"10.36849/JDD.41491","url":null,"abstract":"<p><p>Common signs of skin aging include wrinkles, fine lines, and pigmentary disorders. Patients with skin of color present with unique dermatologic challenges due to differences in how skin conditions manifest on darker skin tones, such as melasma and post-inflammatory hyperpigmentation. As a result, dermatologists and aestheticians need to be aware of these concerns and how to adequately address them. Many prescription and over-the-counter topical medications are now available to treat patients&rsquo; dermatologic conditions. By combining such treatments with in-office physical therapies, an integrated approach to patient skincare is now possible. Therefore, clinicians should be aware of available comprehensive skincare approaches that can be tailored to the individual aesthetic concerns and skin health needs of their patients. J Drugs Dermatol. 2025;24:4(Suppl 1):s5-10.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"41491s5-41491s10"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Utility of Oral Polypodium Leucotomos Extract for Dermatologic Diseases: A Systematic Review.","authors":"Melissa P Zundell, Abigail Katz, Milaan Shah, Joshua Burshtein, Darrell Rigel, Danny Zakria","doi":"10.36849/JDD.8410","DOIUrl":"10.36849/JDD.8410","url":null,"abstract":"<p><strong>Background: </strong>Polypodium leucotomos extract (PLE), a fern plant product with strong anti-inflammatory and immunomodulatory properties, has been employed to reduce photoaging and skin cancer. PLE may also serve as an adjuvant treatment for psoriasis, vitiligo, atopic dermatitis, photodermatoses, and melasma. This systematic review synthesizes the current data on PLE usage to manage dermatological diseases.</p><p><strong>Methods: </strong>This systematic review followed the Agency for Healthcare Research and Quality (AHRQ) Methods Guide for Effectiveness and Comparative Effectiveness Reviews and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIMSA) guidelines. PubMed/MEDLINE, Embase, and Cochrane Library were queried using keywords. Articles were screened for inclusion and subsequently grouped by dermatological condition.</p><p><strong>Results: </strong>Twenty-one of the 152 identified articles met inclusion criteria, including 11 randomized controlled trials and 5 treatment trials. Implicated dermatological conditions were photoaging/skin cancer (9 studies), actinic keratosis (3), photodermatoses (3), melasma (2), vitiligo (3), and atopic dermatitis (1). A thorough article review revealed several potential applications of PLE.</p><p><strong>Conclusion: </strong>PLE exhibits strong therapeutic potential with an encouraging safety profile. It has photoprotective and immunomodulatory properties, underscoring its potential as an adjuvant therapy for multiple dermatological conditions. J Drugs Dermatol. 2025;24(4):346-351. doi:10.36849/JDD.8410R1.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"346-351"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Readability and Content Characterization of Online Reading Materials for Individuals With Vitiligo.","authors":"Arielle Carolina Mora Hurtado, Nada Elbuluk","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"419-420"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-Center, Open-Label Study Study to Evaluate Improvement of Hair Appearance With Novel Hair Growth Serum.","authors":"Suleima Arruda, Alyssa Swearingen, Zahyaa Elmadany, Anna Nakagama, Emely Alvarado Lemoine, Sophia Clara Valmeus, Neil Sadick","doi":"10.36849/JDD.8606","DOIUrl":"10.36849/JDD.8606","url":null,"abstract":"<p><strong>Background: </strong>REVIVV&reg; is a topical hair growth serum with a proprietary formula of botanicals that addresses multiple factors involved in hair loss pathophysiology. This open-label, prospective, single-center study evaluated the efficacy of REVIVV&reg;, a topical hair growth serum, in 20 adults (10 male, 10 female) with mild to moderate hair loss over 6 months. Participants applied the serum twice daily, and assessments were conducted at baseline, 4, 12, and 24 weeks. Dermatologist evaluations and patient self-assessments of hair quality and growth were performed using a 7-point Likert scale. Results Investigator-rated improvements in hair quality and growth increased from 0.75 and 0.81 at 4 weeks to 1.73 and 1.83 at 24 weeks, respectively. Patient-reported assessments showed that 85% of participants noted improved hair quality and growth at 24 weeks, with 50% reporting great improvement. Patient satisfaction was high, with 80% of participants being moderately or greatly satisfied at 4 weeks, increasing to 95% at 24 weeks. No adverse events related to the serum were reported throughout the study. The results demonstrate that twice-daily application of REVIVV&reg; &nbsp;over 6 months is associated with increased hair growth and improved hair quality suggesting that REVIVV&reg; &nbsp;may be an effective, non-pharmacological option for individuals seeking to improve hair growth and quality. J Drugs Dermatol. 2025;24(4):394-396. doi:10.36849/JDD.8606&nbsp.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"394-396"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acetyl Hexapeptide-8 as a Topical Alternative to Botulinum Toxin: A Review of the Literature.","authors":"Kalisa Lum, Milan M Hirpara, Christine Pham, Megan Nguyen, Natasha Mesinkovska","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"e31-e32"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Innovative Cream Improves Signs and Symptoms of Dermatoporosis in Patients Aged 65 and Over.","authors":"Alan Widgerow, Mathieu Grivet-Seyve, Sarah Anjuwon, Christine Emesiani, Matthew Meckfessel","doi":"10.36849/JDD.8947","DOIUrl":"10.36849/JDD.8947","url":null,"abstract":"<p><strong>Background: </strong>There is increasing recognition of dermatoporosis - a condition of chronic cutaneous fragility of aging skin seen primarily in older adults. Dermatoporosis can be characterized by white pseudo scars, purpura/bruising, skin thinning, and loss of volume. This study evaluated a novel cream with microdoses of mandelic acid and Centella asiatica that was formulated to target physiologic processes involved in dermatoporosis.</p><p><strong>Methods: </strong>A 12-week, proof-of-concept study of participants aged 65 years and older (n=54) with sensitive skin and dermatoporosis managed with twice-daily application of the cream on both forearms and 1 leg (randomly selected, with the other leg serving as control). Key assessments included transepidermal water loss (TEWL), skin thickness measurement by ultrasound, clinical scoring for dryness and roughness, a participant questionnaire, and standard safety assessments.</p><p><strong>Results: </strong>Twice-daily use of the novel cream resulted in an ongoing consistent positive increase in skin thickness of 5% (P&lt;0.05), with improvements primarily in the dermis and epidermis but also notable in the subdermal layer. Significant improvements in hydration were observed starting from Day 7 and observed through Day 84 (or end of study) (P&lt;0.05). Changes in TEWL showed a 20% improvement in barrier function that also was apparent early (Day 7) and sustained through the study (40% improvement at day 84, P&lt;0.05). The cream demonstrated excellent safety with no adverse reactions and no worsening in tolerability parameters.</p><p><strong>Conclusions: </strong>This cream, containing microdoses of mandelic acid and Centella asiatica, safely and effectively improved skin thickness, firmness, and resiliency, and had high acceptability with study participants. J Drugs Dermatol. 2025;24(4):352-356. doi:10.36849/JDD.8947.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"24 4","pages":"352-356"},"PeriodicalIF":1.5,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143803589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}